Neurotrophic keratopathy is a rare degenerative disease of the cornea characterized by reduction or loss of corneal sensitivity that can be asymptomatic or present with red-eye and, during the early s...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for neurotrophic keratopathy is limited primarily due to its rarity, which affects fewer than 200,000 people in the U.S. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on the condition. Additionally, the absence of identified genes and established inheritance patterns complicates the understanding of its clinical features.
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
There are currently 15 active clinical trials investigating various treatments for neurotrophic keratopathy. Notably, the FDA has approved cenegermin-bkbj as a treatment option. Other drugs in development include allogeneic human blood serum, exosomes purified from primed human bone marrow derived mesenchymal stem cells, and several peptides. For more information on ongoing trials, you can visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neurotrophic%20keratopathy.
Actionable guidance for navigating care for neurotrophic keratopathy
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for neurotrophic keratopathy is limited primarily due to its rarity, which affects fewer than 200,000 people in the U.S. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on the condition. Additionally, the absence of identified genes and established inheritance patterns complicates the understanding of its clinical features.
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
There are currently 15 active clinical trials investigating various treatments for neurotrophic keratopathy. Notably, the FDA has approved cenegermin-bkbj as a treatment option. Other drugs in development include allogeneic human blood serum, exosomes purified from primed human bone marrow derived mesenchymal stem cells, and several peptides. For more information on ongoing trials, you can visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neurotrophic%20keratopathy.
Actionable guidance for navigating care for neurotrophic keratopathy
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for neurotrophic keratopathy is limited primarily due to its rarity, which affects fewer than 200,000 people in the U.S. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on the condition. Additionally, the absence of identified genes and established inheritance patterns complicates the understanding of its clinical features.
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
There are currently 15 active clinical trials investigating various treatments for neurotrophic keratopathy. Notably, the FDA has approved cenegermin-bkbj as a treatment option. Other drugs in development include allogeneic human blood serum, exosomes purified from primed human bone marrow derived mesenchymal stem cells, and several peptides. For more information on ongoing trials, you can visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neurotrophic%20keratopathy.
Actionable guidance for navigating care for neurotrophic keratopathy
To navigate your care for neurotrophic keratopathy, consider seeking a cornea specialist or an ophthalmologist with expertise in corneal diseases. You may also want to explore clinical trials that could provide access to new treatments. The National Institutes of Health's Genetic and Rare Diseases Information Center (GARD) offers valuable resources at rarediseases.info.nih.gov. Additionally, inquire about participating in any natural history studies related to your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 8 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.